Most Read Articles
Roshini Claire Anthony, 3 days ago

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

3 days ago
Waist circumference (WC) trajectories are predictive of altered risk of cardiovascular disease (CVD) among adults, even among those without body mass index (BMI)-defined obesity, a study has shown. Such association appears higher in younger adults.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Novel cyclosporine formulation delivers in dry eye disease

06 Feb 2021

Cyclosporine in the form of an ophthalmic gel is safe and effective in the treatment of dry eye disease (DED), according to the results of a phase II trial.

The trial randomized 240 patients with moderate-to-severe DED to receive one of the following treatments: CyclAGel 0.05% once daily (QD; n=59), CyclAGel 0.05% twice daily (BID; n=60), CyclAGel 0.1% QD (n=60), and restasis 0.05% BID (n=61) for 12 weeks. Treatment was initiated after receiving BID dosing of hypromellose eye drops during a 2-week run-in period.

Efficacy was evaluated based on a number of sign and symptom outcomes, including eye dryness score (visual analogue scale [VAS]), six other parameters of symptoms for dryness (burning/stinging, itching, foreign body sensation, discomfort, sensitivity to light, and pain), and corneal fluorescein staining. The Schirmer test was used to assess dry eye symptoms (VAS severity) at visit 3 (week 2), visit 4 (week 6), and visit 5 (week 12).

Compared with restasis, CyclAGel produced a consistent improvement in eye dryness score and the six other parameters of symptoms for dryness, corneal fluorescein staining, breakup time, and Schirmer test scores over the 12-week treatment period.

However, no significant differences between CyclAGel and restasis were seen after baseline corrections were made. The results of the full analysis set remained consistent with those of the per-protocol set (p>0.05).

Each CyclAGel regimen (0.05% QD, 0.05% BID, and 0.1% QD) demonstrated better effects than restasis, with the 0.05% QD dosing providing the greatest benefit.

The incidence rate of ocular-related treatment-emergent adverse events (TEAEs) was low across all treatment groups, with no serious drug-related TEAEs.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

3 days ago
Waist circumference (WC) trajectories are predictive of altered risk of cardiovascular disease (CVD) among adults, even among those without body mass index (BMI)-defined obesity, a study has shown. Such association appears higher in younger adults.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.